• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
GRTS

GRTS

Gritstone bio, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.03

-0.01 (-31.78%)

Company Profile

CEO

Andrew R. Allen BCh, BM, MA, MRCP,

IPO Date

2018-09-28

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.04

Prev. Close

$0.05

Day Low

$0.03

Day High

$0.04

52W Low

$0.03

52W High

$3.17

Market Cap

$0.00B

Volume

55.25M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

41.3%

Avg Negative

2.9%

Avg Neutral

55.9%

News Feed

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire·6/17/2021·↑ positive

Gritstone: Interesting Covid Player, Highly Differentiated Market

Seeking Alpha·5/21/2021·↑ positive

Gritstone Oncology, Inc. (GRTS) Q1 Earnings and Revenues Top Estimates

Zacks Investment Research·5/6/2021·↑ positive

Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC

GlobeNewsWire·3/29/2021·↑ positive

Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research·3/11/2021·↑ positive

Gritstone Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

GlobeNewsWire·3/11/2021·↑ positive

Gritstone Announces Promotions Within its Leadership Team

GlobeNewsWire·3/8/2021·↑ positive

Moving Average Crossover Alert: Gritstone Oncology (GRTS)

Zacks Investment Research·1/27/2021·↑ positive

Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up

Zacks Investment Research·1/20/2021·↑ positive

Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

GlobeNewsWire·1/20/2021·↑ positive